Please login to the form below

Not currently logged in
Email:
Password:

Relovair

This page shows the latest Relovair news and features for those working in and with pharma, biotech and healthcare.

COPD-asthma market to reach $47bn in 2017

These medicines include SkyePharma's Flutiform (fluticasone/formoterol) to treat asthma, Novartis' Arcapta Neohaler for patients with COPD, and GSK's own Seretide follow-up Relvar (formerly Relovair) for both asthma

Latest news

More from news
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest Intelligence

  • Interview: Deepak Khanna, ABPI Interview: Deepak Khanna, ABPI

    Referencing a 'real-world' study into GlaxoSmithKline's (GSK) Relovair in Salford, he says: “ We have a good example where the NHS partnered with three companies to focus on COPD.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics